Table 3.
Risk of disease by categories of serum uric acid of baseline (raw percentages) (uric acid is from baseline. All diseases are from 2017 follow-up data).
| Variables | Serum uric acid quartile(mg/dL) (Men) | Serum uric acid quartile(mg/dL) (Women) | ||||||
|---|---|---|---|---|---|---|---|---|
| ≤4.52 | 4.53–5.34 | 5.35–6.33 | ≥6.34 | ≤4.52 | 4.53–5.34 | 5.35–6.33 | ≥6.34 | |
| Heart failure | ||||||||
| No. of subjects: n (heart failure subjects) | 97 (24) | 152 (48) | 205 (48) | 256 (60) | 331 (78) | 249 (79) | 212 (67) | 133 (43) |
| No. of incidents of HF(rate: %) | 42 (10.32) | 80 (11.94) | 106 (11.88) | 124 (10.72) | 141 (9.32) | 122 (10.77) | 107 (11.33) | 89 (14.26) |
| Person-years | 407 | 670 | 892 | 1,157 | 1,513 | 1,133 | 944 | 624 |
| Crude 95% CI | 1 | 1.37 (0.71–2.65) | 0.87 (0.44–1.71) | 1.21 (0.65–2.25) | 1 | 1.15 (0.79–1.69) | 1.09 (0.73–1.63) | 1.14 (0.71–1.83) |
| Adjusted 95% CI | 1 | 1.18 (0.60–2.32) | 0.73 (0.36–1.47) | 0.86 (0.43–1.72) | 1 | 1.27 (0.86–1.88) | 1.30 (0.85–1.99) | 1.55 (0.90–2.67) |
| Heart disease events | ||||||||
| No. of subjects | 104 (59) | 164 (93) | 227 (139) | 279 (177) | 353 (201) | 265 (168) | 225 (152) | 141 (99) |
| No. of incidents of HD event (rate: %) | 20 (4.23) | 34 (4.55) | 35 (3.28) | 53 (4.14) | 83 (5.13) | 55 (4.45) | 63 (6.26) | 28 (4.05) |
| Person-years | 473 | 748 | 1,067 | 1,280 | 1,618 | 1,236 | 1,006 | 692 |
| Crude 95% CI | 1 | 0.77 (0.34–1.71) | 0.90 (0.44–1.86) | 0.77 (0.37–1.57) | 1 | 0.88 (0.55–1.39) | 0.70 (0.42–1.17) | 0.61 (0.32–1.18) |
| Adjusted 95% CI | 1 | 0.80 (0.35–1.82) | 0.93 (0.43–1.99) | 0.79 (0.35–1.77) | 1 | 0.91 (0.57–1.46) | 0.77 (0.44–1.33) | 0.73 (0.35–1.53) |
| Atrial fibrillation | ||||||||
| No. of subjects | 101 (3) | 159 (5) | 221 (16) | 272 (13) | 343 (18) | 262 (9) | 222 (6) | 137 (8) |
| No. of incidents of AF (rate: %) | 5 (1.05) | 7 (0.92) | 19 (1.81) | 24 (1.84) | 28 (1.7) | 16 (1.26) | 16 (1.51) | 17 (2.47) |
| Person-years | 474 | 765 | 1,051 | 1,302 | 1,648 | 1,270 | 1,061 | 687 |
| Crude 95% CI | 1 | 0.66 (0.13–3.26) | 1.52 (0.42–5.51) | 1.08 (0.29–4.01) | 1 | 0.76 (0.30–1.93) | 0.73 (0.28–1.95) | 1.71 (0.70–4.19) |
| Adjusted 95% CI | 1 | 0.66 (0.13–3.35) | 1.74 (0.45–6.75) | 1.49 (0.35–6.23) | 1 | 0.80 (0.31–2.09) | 0.80 (0.28–2.28) | 2.19 (0.78–6.19) |
| Diabetes | ||||||||
| No. of subjects | 101 (26) | 162 (39) | 216 (62) | 273 (74) | 346 (91) | 259 (78) | 224 (69) | 139 (46) |
| No. of incidents of DM (rate: ‰) | 7 (1.49) | 15 (1.93) | 32 (3.10) | 44 (3.41) | 38 (2.29) | 36 (2.90) | 36 (3.44) | 25 (3.61) |
| Person-years | 470 | 776 | 1,033 | 1,290 | 1,656 | 1,242 | 1,047 | 692 |
| Crude 95% CI | 1 | 1.30 (0.53–3.18) | 2.07 (0.91–4.69)* | 2.28 (1.03–5.06)* | 1 | 1.26 (0.80–1.99) | 1.50 (0.95–2.36)* | 1.56 (0.94–2.59)* |
| Adjusted 95% CI | 1 | 1.29 (0.52–3.21) | 1.98 (0.85–4.58) | 2.08 (0.89–4.85)* | 1 | 1.12 (0.70–1.78) | 1.29 (0.80–2.08) | 1.24 (0.70–2.21) |
| Hypertension | ||||||||
| No. of subjects | 97 (35) | 154 (68) | 216 (102) | 274 (137) | 337 (150) | 259 (124) | 218 (103) | 130 (72) |
| No. of incidents of Hypertension (rate: ‰) | 23 (5.19) | 44 (6.15) | 86 (8.90) | 96 (7.75) | 121 (7.75) | 86 (7.34) | 94 (9.75) | 59 (9.38) |
| Person-years | 443 | 715 | 966 | 1,239 | 1,562 | 1,172 | 964 | 629 |
| Crude 95% CI | 1 | 1.17 (0.71–1.94) | 1.68 (1.06–2.66)* | 1.47 (0.94–2.32)* | 1 | 0.94 (0.71–1.24) | 1.24 (0.95–1.63) | 1.17 (0.85–1.59) |
| Adjusted 95% CI | 1 | 1.20 (0.72–1.99) | 1.72 (1.07–2.77)* | 1.54 (0.94–2.51)* | 1 | 1.00 (0.76–1.33) | 1.28 (0.96–1.70)* | 1.18 (0.82–1.68) |
| Metabolic syndrome | ||||||||
| No. of subjects | 95 (29) | 148 (56) | 202 (83) | 256 (125) | 323 (196) | 239 (165) | 207 (169) | 123 (102) |
| No. of incidents of Mt Syndrome (rate: %) | 20 (4.48) | 29 (4.03) | 58 (6.04) | 68 (5.60) | 99 (6.40) | 57 (4.95) | 42 (4.21) | 16 (2.49) |
| Person-years | 446 | 719 | 960 | 1,214 | 1,546 | 1,152 | 998 | 643 |
| Crude 95% CI | 1 | 0.90 (0.51–1.59) | 1.35 (0.81–2.25) | 1.26 (0.76–2.07) | 1 | 0.77 (0.56–1.07) | 0.66 (0.46–0.95)** | 0.39 (0.23–0.66)** |
| Adjusted 95% CI | 1 | 1.01 (0.57–1.80) | 1.61 (0.95–2.72)* | 1.61 (0.93–2.77)* | 1 | 0.96 (0.69–1.35) | 0.84 (0.58–1.23) | 0.56 (0.31–1.01)* |
| Kidney disease(eGFR) | ||||||||
| No. of subjects | 98 (13) | 160 (38) | 215 (65) | 269 (119) | 346 (81) | 256 (93) | 221 (93) | 134 (70) |
| No. of incidents of kidney disease (rate: %) | 20 (4.52) | 35 (4.78) | 37 (3.65) | 71 (5.77) | 70 (4.39) | 65 (5.49) | 53 (5.28) | 33 (4.99) |
| Person-years | 442 | 732 | 1,014 | 1,230 | 1,596 | 1,185 | 1,004 | 661 |
| Crude 95% CI | 1 | 1.06 (0.61–1.83) | 0.80 (0.46–1.38) | 1.26 (0.77–2.08) | 1 | 1.24 (0.88–1.74) | 1.20 (0.84–1.71) | 1.10 (0.73–1.66) |
| Adjusted 95% CI | 1 | 1.03 (0.59–1.79) | 0.78 (0.45–1.36) | 1.23 (0.73–2.06) | 1 | 1.18 (0.83–1.67) | 1.03 (0.71–1.50) | 0.84 (0.53–1.36) |
*
p < 0.10;
**
p < 0.05. Bold values are statistically significant.